Plasma Levels of GDF-9 and GDF-15 in Patients With Polycystic Ovary Syndrome.

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2012 by Ankara Education and Research Hospital.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Ankara Education and Research Hospital
ClinicalTrials.gov Identifier:
NCT01644305
First received: July 17, 2012
Last updated: July 18, 2012
Last verified: July 2012

July 17, 2012
July 18, 2012
Not Provided
Not Provided
The association of GDF 9 AND GDF 15 with bone and cardiovascular parameters in women with polycystic ovary syndrome
Same as current
Complete list of historical versions of study NCT01644305 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Plasma Levels of GDF-9 and GDF-15 in Patients With Polycystic Ovary Syndrome.
Not Provided

The purpose of this study is to determine the plasma levels of GDF-9 and GDF-15, and their association with bone and cardiovascular parameters in patients with Polycystic Ovary Syndrome.

Not Provided
Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Probability Sample

Hospital Endocrinology Outpatient Clinic

Polycystic Ovary Syndrome
Not Provided
  • Polycystic Ovary Syndrome
  • Idiopathic hirsutism
  • Control
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Female patients at ages 25-35 diagnosed with polycystic ovarian syndrome and idiopathic hirsutism

Exclusion Criteria:

  • acute infectious disease, a thyroid, pituitary, nutritional, inflammatory, hepatic, renal, or neoplastic disorder; history of cardiovascular disease or pulmonary embolism; a family history of coronary artery disease; smoking history; hypertension; diabetes mellitus; use of oral contraceptives, anti-androgens and drugs known to interfere with cytokine release, such as corticosteroids, immunosuppressors, or nonsteroidal antiinflammatory drugs.

any medication known to affect hormonal or metabolic parameters.

Female
25 Years to 35 Years
Not Provided
Contact information is only displayed when the study is recruiting subjects
Turkey
 
NCT01644305
3849
Not Provided
Not Provided
Ankara Education and Research Hospital
Not Provided
Not Provided
Ankara Education and Research Hospital
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP